SWM
ATXS

SeaCrest Wealth Management’s Astria Therapeutics ATXS Stock Holding History

SeaCrest Wealth Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-71
Closed -$3K – 613
2019
Q1 		$3K Buy
+71
New +$2.41K ﹤0.01% 1825

Other funds holding ATXS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

SeaCrest Wealth Management's ATXS Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Astria Therapeutics (ATXS) in Q2 2019, closing a stake of 71 shares — an estimated $3K sold.

SeaCrest Wealth Management first reported a position in ATXS in Q1 2019 and held it in 1 quarter. The position peaked at $3K in Q1 2019. 24 funds tracked by Wall St. Rank hold ATXS as of Q2 2019.

  • SeaCrest Wealth Management reported no remaining Astria Therapeutics position as of Q2 2019 after selling out during the quarter.
  • SeaCrest Wealth Management sold 71 Astria Therapeutics shares in Q2 2019, an estimated $3K.
  • SeaCrest Wealth Management first reported a position in Astria Therapeutics in Q1 2019 and held it in 1 quarter.
  • SeaCrest Wealth Management's Astria Therapeutics position peaked at $3K in Q1 2019.
  • 24 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.